Pancreatic Involvement by Plasma Cell Neoplasms by Lopes da Silva, R
REVIEW
Pancreatic Involvement by Plasma Cell Neoplasms
Rodrigo Lopes da Silva
Published online: 16 August 2011
# Springer Science+Business Media, LLC 2011
Abstract
Introduction Pancreatic involvement by plasma cell neo-
plasms is an extremely rare event, with only 50 cases
described in the literature. They can present as a primary
solitary extramedullary plasmacytoma or plasmacytoma
secondary to a plasma cell myeloma. Clinical manifesta-
tions are due to the presence of a pancreatic mass usually in
the pancreas head, which causes extra-biliary obstruction
and abdominal pain.
Methods Abdominal imaging including CT scan or endo-
scopic ultrasound with fine-needle aspiration tissue sampling
is essential for the initial diagnostic procedure. However,
immunohistochemical analysis of the biopsy specimen or
flow cytometry of the aspirated material is crucial to prove the
monoclonality and the final diagnosis of a plasma cell
neoplasm.
Discussion Management of these situations include radio-
therapy, chemotherapy, surgery or combined therapy. Novel
medications including the immunomodulatory drugs or the
proteasome inhibitors followed by consolidation with
intensive chemotherapy and haematopoietic stem cell
transplantation are nowadays used as upfront treatment in
the cases associated to a plasma cell myeloma.
Conclusion Despite the rarity, plasma cell neoplasms
should be considered in the differential diagnosis of
obstructive jaundice and pancreatic neoplasms since they
are potentially treatable situations.
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Introduction
Pancreatic involvement in haematologic malignancies is quite
an uncommon event. Whilst primary lymphomas of this organ
are rare with about 150 cases reported so far [1], on the other
hand, plasma cell neoplasms (PCN) are even more uncommon
in this organ. PCN are clonal diseases of terminally
differentiated B cells that secret a monoclonal immunoglob-
ulin also called paraprotein or M-protein. The spectrum of
PCN encompasses various entities: monoclonal gammopathy
of undetermined significance (MGUS); plasma cell myeloma
(PCM) variants smoldering, symptomatic, non-secretory and
plasma cell leukaemia; plasmacytoma (solitary plasmacytoma
of bone, extraosseous/extramedullary plasmacytoma); immu-
noglobulin deposition diseases (primary amyloidosis, systemic
light and heavy-chain deposition diseases); and osteosclerotic
myeloma/POEMS syndrome) [2]. Among those, only primary
extramedullary plasmacytoma (EMP) and secondary plasma-
cytoma due to a PCM have been found to affect the pancreas
and cause relevant disease. Primary amyloidosis is caused by
a plasma cell or a lymphoplasmacytic neoplasm that secretes
intact or fragments of abnormal immunoglobulin light chain
or, rarely, heavy chains which accumulate in many tissues in
the form of AL amyloid. Although amyloid deposits in
pancreatic islets occur in systemic AL amyloidosis, they do
not disturb the pancreatic function, whilst other types of
amyloid proteins not related to a PCN, namely amylin (islet
amyloid polypeptide), are responsible for the pathogenesis of
type II diabetes mellitus [3, 4].
R. Lopes da Silva (*)
Hospital Santo António dos Capuchos–CHLC,
Alameda Santo António dos Capuchos,
1169-050 Lisbon, Portugal
e-mail: ronolosi@gmail.com
J Gastrointest Canc (2012) 43:157–167
DOI 10.1007/s12029-011-9314-9
Osteosclerotic myeloma/POEMS syndrome is a plasma
cell neoplasm characterized by fibrosis and osteosclerotic
changes in bone trabecula and lymph node, and is
component of a broader syndrome that includes polyneur-
opathy, organomegaly, endocrinopathy, monoclonal gamm-
opathy and skin changes. The endocrinopathy spectrum
includes hyperglycaemia and blood glucose intolerance that
is not related to a direct pancreatic endocrine damage or
dysfunction from a PCN but to the imbalance of pro-
inflammatory cytokines, namely the vascular endothelial
growth factor [5]. Since only primary and secondary
plasmacytomas have been found to cause relevant abdom-
inal and pancreatic clinical manifestations, focus will be
given to these two entities. Primary EMPs are localized
plasma cell neoplasms arising in tissues other than the bone
and constitute 3–5% of all PCN, with a strong male
predominance (2/3) and median age at diagnosis of 55 years
(10 years younger than in plasma cell myeloma patients).
About 80% of primary EMP affect the upper respiratory
tract (oropharynx, nasopharynx, sinuses, larynx) and the
remaining occurring in diverse anatomic sites including
lymph nodes, bladder, central nervous system, breast,
thyroid, testis, parotid, skin and gastrointestinal tract
(stomach, small intestine, colon, liver and pancreas) [6].
PCM accounts for approximately 1% of all malignancies
tumours and 10–15% of haematopoietic neoplasms. It is
more common in men than in women (1.4:1) and has
median age of presentation of about 65 years, but in
uncommon cases, it can occur in the second decade of life
[7, 8]. It can be asymptomatic or manifest in aggressive
form, and the manifestations are related to the deposition
of abnormal immunoglobulin chains in the tissues. Bone
marrow involvement is typically present especially in
areas of active haematopoiesis. Lytic bone lesions and
focal tumoral masses (secondary plasmacytomas) also
occur, and extramedullary disease is associated with
advanced-stage disease. It is thought that chronic anti-
genic stimulation from infection, toxins, chronic disease
or radiation may predispose for an increased incidence of
PCM; however, most patients do not have an identifiable
or explainable cause.
Diagnostic Criteria
It is very important to know whether a pancreatic mass
known to be a plasmacytoma is just a primary EMP or is
secondary to a PCM because the therapeutic strategies are
different, being more aggressive in the latter case due to the
required combination of diverse modalities of treatments,
whilst EMP can often be cured with local radiation only. To
facilitate this distinction, diagnostic criteria for primary
EMP and secondary plasmacytomas due to PCM have been
proposed [2, 9]
– Primary EMP diagnostic criteria [2]
1. Absence of M-protein in serum and/or urine
2. More than one localized area of extramedullary
tumour of clonal plasma cells that may be recurrent
3. Normal bone marrow
4. No abnormalities in skeletal survey or MRI
5. No any evidence of organ or tissue impairment
– Secondary EMP diagnostic criteria [9]
1. Presence of M-protein in serum or urine (any level)
2. Presence of bone marrow clonal plasma cell or
plasmacytoma
3. Manifestations of end-organ damage including
anaemia, hypercalcemia, lytic bone lesions, renal
insufficiency, hyperviscosity, amyloidosis or recurrent
infections
Of particular relevance to underscore is that almost 50%
of patients with primary EMP have small levels of
detectable M-protein in the serum or urine that generally
disappear after therapy institution. Persistence of M-protein
after treatment may indicate an underlying MGUS or the
presence of multiple focal lesions often secondary to an
evolving PCM.
Incidence
Pancreatic involvement by PCN is extremely rare, comprising
<0.1% of all pancreatic masses. The diagnosis was often made
postmortem with an incidence rate of 2.3% based on autopsy
studies, but with the development of more sophisticated
imaging techniques, the diagnosis is nowadays made when
the patient is still alive, by image-guided biopsy/fine-needle
aspiration followed by immunohistochemical or flow cytom-
etry characterization of the specimen. Since the first descrip-
tion in 1947, only 50 cases of primary EMP or plasmacytomas
secondary to PCM have been reported so far in the literature
[10–58]. A summary of all the reported cases including
patient data, type of disease, manifestations and treatment is
depicted below (Tables 1 and 2).
Location of the Pancreatic Lesions
About 80% of pancreatic EMPs are located in the head of
the pancreas, whilst the remaining 20% are found in the
body and the tail of the organ. Most are single lesions; in
some cases, two or more concurrent lesions may occur, and
even more rarely, the lesion has its epicentre in another
abdominal organ but is large enough to affect the pancreas
too, mainly the pancreatic tail [32, 41, 42] (Fig. 1a, b).
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Table 1 Patients´ characteristics, type of disease, pancreatic location of the mass and lesions in other anatomic sites
Cases Age (years) Gender Type of plasmacytoma Pancreatic site Other site(s)
Hefferman (1947) NA NA NA Head Duodenum
Richards et al. (1958) NA NA NA Head NA
Doutre et al. (1976) NA NA NA Head NA
Simon et al. (1978) 68 M Secondary Head Lung, bronchi
Rice et al. (1981) 54 M Secondary Head None
Bell et al. (1982) 88 M Secondary Head/body Lymph nodes, liver
Twomey et al. (1983) 58 F Primary Head Kidneys
Borgia et al. (1984) 77 M Secondary Head None
Helenon et al. (1984) 60 F Secondary Head None
Jaubert et al. (1985) 75 F Primary Head None
Gorg et al. (1985) 61 M Primary Head Pleura
Mitchell et al. (1985) 69 M Secondary Head None
Speelberg et al. (1985) 57 F Secondary Head None
Zafaranloo et al. (1986) 67 M Secondary Head None
Scheinman et al. (1987) 29 F Primary Head/body/tail Maxillary sinus
Akiyama et al. (1988) 59 F Primary Head Abdominal
Fukuya et al. (1989) 48 M Primary Head Epipharynx
Wilson et al. (1989) 52 F Secondary Head Pelvic
Brichon et al. (1989) NA NA NA NA NA
Hamamoto et al. (1990) 63 M Secondary Head Pleura
Fischer et al. (1991) 45 M Secondary Head None
Davidson et al. (1993) NA NA NA NA NA
Olson et al. (1993) 65 M Secondary Head None
Fautrel et al. (1993) 58 M Primary Head Liver
Tanaka et al. (1993) 46 M Primary Tail Retroperitoneal space, spleen, stomach, intestine, kidney
Dodd et al. (1994) 55 F Secondary Head None
67 M Secondary Head None
Ohno et al. (1994) 62 F Secondary Tail Spleen, stomachadrenal gland, kidney
Abu-Hammour et al. (1996) 61 M Secondary Head None
Pääkkö et al. (1998) 70 M Secondary Head None
Hameed et al. (2000) NA NA NA Head NA
Rios et al. (2000) 68 M Secondary Head None
Hirata et al. (2002) 33 M Primary Head/tail Maxillary sinus
Balliu et al. (2003) 32 F Secondary Head/body/tail None
Hiller et al. (2004) 82 F Secondary Head Sacral, skull base
Coban et al. (2004) 75 M Secondary Head None
Deguchi et al. (2004) 56 M Primary Tail Lymph nodes
Kazama et al. (2005) 70 F Secondary Head/body Stomach, bladder
Ali et al. (2007) 64 M Secondary Head Chest wall
Atiq et al. (2009) 49 F Secondary Body None
Gupta et al. (2009) 52 M Secondary Head Jejunum
Spiegel et al. (2009) 37 M Secondary Head/body None
Leake et al. (2009) 46 M Secondary Head None
Wei et al. (2009) 53 F Primary Head Left shoulder
Annibali et al. (2009) 56 M Secondary Head None
Padda et al. (2010) 75 M Secondary Head/proximal body Stomach
Coss et al. (2010) 74 M Secondary Head None
Artifon et al. (2010) 57 M Secondary Head None
Padda et al. (2010) 75 M Secondary Head Stomach
Pinto-Marques et al. (2010) 64 F Secondary Head None
M male, F female, NA not available
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Table 2 Pancreatic location of the mass(es), clinical manifestations and treatment
Cases Pancreatic site Clinical manifestations Treatment
Hefferman (1947) Head Duodenum NA
Richards et al. (1958) Head NA NA
Doutre et al. (1976) Head NA NA
Simon et al. (1978) Head Obstructive jaundice RT
Rice et al. (1981) Head Obstructive jaundice NA
Bell et al. (1982) Head/Body Obstructive jaundice RT
Twomey et al. (1983) Head Obstructive jaundice RT
Borgia et al. (1984) Head Obstructive jaundice RT
Helenon et al. (1984) Head Obstructive jaundice RT
Jaubert et al. (1985) Head Obstructive jaundice Surgery
Gorg et al. (1985) Head Obstructive jaundice RT
Mitchell et al. (1985) Head Obstructive jaundice RT
Speelberg et al. (1985) Head Obstructive jaundice NA
Zafaranloo et al. (1986) Head Obstructive jaundice RT
Scheinman et al. (1987) Head/body/tail Obstructive jaundice RT+surgery
Akiyama et al. (1988) Head Obstructive jaundice RT
Fukuya et al. (1989) Head Obstructive jaundice RT
Wilson et al. (1989) Head Abdominal pain, nausea RT
Brichon et al. (1989) NA NA NA
Hamamoto et al. (1990) Head Obstructive jaundice Chemo
Fischer et al. (1991) Head Obstructive jaundice RT
Davidson et al. (1993) NA NA NA
Olson et al. (1993) Head(2 L) Obstructive jaundice RT+chemo
Fautrel et al. (1993) Head Obstructive jaundice RT+surgery
Tanaka et al. (1993) Tail Abdominal pain Chemo+surgery
Dodd et al. (1994) Head Obstructive jaundice NA
Head Obstructive jaundice NA
Ohno et al. (1994) Tail Pancreatitis Chemo
Abu-Hammour et al. (1996) Head Obstructive jaundice RT
Pääkkö et al. (1998) Head Obstructive jaundice NA
Hameed et al. (2000) Head Obstructive jaundice NA
Rios et al. (2000) Head Obstructive jaundice RT+chemo
Hirata et al. (2002) Head/tail (2L) Abdominal pain RT
Balliu et al. (2003) Head/body/tail Obstructive jaundice Surgery
Hiller et al. (2004) Head Nausea RT
Coban et al. (2004) Head Obstructive jaundice RT
Deguchi et al. (2004) Tail NA Surgery (distal pancreatectomy
Kazama et al. (2005) Head/Body Obstructive jaundice, abdominal pain RT+chemo
Ali et al. (2007) Head Obstructive jaundice RT
Atiq et al. (2009) Body Pancreatitis, GI bleeding Chemo→HSCT
Gupta et al. (2009) Head Obstructive jaundice NA
Spiegel et al. (2009) Head/body Obstructive jaundice, abdominal pain Chemo→HSCT
Leake et al. (2009) Head Obstructive jaundice, back pain, GI bleeding None
Wei et al. (2009) Head Obstructive jaundice Chemo→Bortezomib
Annibali et al. (2009) Head Obstructive jaundice, abdominal pain Chemo
Padda et al. (2010) Head/proximal body Obstructive jaundice RT
Coss et al. (2010) Head Obstructive jaundice RT+surgery
Artifon et al. (2010) Head Obstructive jaundice Chemo
Padda et al. (2010) Head Obstructive jaundice RT
Pinto-Marques et al. (2010) Head Asymptomatic NA
NA not available/not stated, RT radiotherapy, Chemo chemotherapy, HSCT haematopoietic stem cell transplantation
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Clinical Manifestations
Symptoms from pancreatic EMPs depend on the site of the
tumour, tumour size, and compression and/or involvement of
the surrounding structures. Since most of them occur in the
pancreas head, obstructive jaundice is by far the commonest
symptom followed by abdominal pain. Pancreatitis, gastroin-
testinal bleeding and nausea have also been described in cases
where a bulky mass was present. Rare cases detected in the
early course of the disease are asymptomatic (Fig. 2).
Diagnosis
Abdominal Imaging/Procedures
Pancreatic involvement by PCN is rare and presents
nonspecific radiologic features. Poorly differentiated pan-
creatic neoplasms and lymphoma may be difficult to
differentiate from EMP. It is very difficult to radiologically
differentiate EMP of the pancreas from other pancreatic
tumours, especially those which show enhancement with
intravenous contrast such as endocrine cell tumours and
acinar cell neoplasms. Although it cannot make the
diagnosis, imaging plays a key role since it identifies the
location of the lesion and guides the biopsy.
Transcutaneous Ultrasonography
Transcutaneous ultrasonography (TUS) is very useful as an
initial screening test in evaluating patients who present with
possible obstructive jaundice. By helping detect intra-
hepatic or extrahepatic bile duct dilation, abdominal
ultrasonography can rapidly and accurately assess whether
or not a patient has biliary obstruction. Although less
expensive and generally more readily available than
computed tomography (CT) scanning, TUS has less utility
than CT scanning because the pancreas is often obscured by
overlying gas from the stomach, duodenum, and colon and
the depth of the pancreas from the abdominal wall limits
TUS imaging to lower frequency (2–5 MHz); thus, a lower-
resolution ultrasonographic image is obtained. Therefore,
TUS can help detect only 60–70% of pancreatic masses,
and similar to CT scanning, more than 40% of the lesions
smaller than 3 cm are missed. On TUS, pancreatic
infiltration by EMP has been described as a heterogeneous
focal mass most often located in the head of the pancreas
that is hypoechoic relative to the normal parenchyma and
shows fine internal echoes [21, 42].
Endoscopic Ultrasonography
Endoscopic ultrasonography (EUS) has a proven record for
staging pancreatic cancer and for cytological evaluation.
This technique has increasingly been used to obtain
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material by fine-needle aspiration. EUS obviates the
physical limitations of TUS by placing a high-frequency
ultrasonographic transducer on an endoscope, which is then
positioned in the stomach or duodenum endoscopically to
help visualize the head, body and tail of the pancreas.
Because of the proximity of the pancreas to the EUS
transducer, high-frequency ultrasonography (7.5–12 MHz)
can be used to produce very high-resolution (sub-
millimetres) images. Where expert EUS is available, it
has been proven to be the most sensitive and specific
diagnostic test for pancreatic cancer. EUS has detection
rates of 99–100% for all pancreatic carcinomas, including
those smaller than 3 cm. A negative endoscopic
ultrasound is nearly 100% specific at ruling out the
presence of a pancreatic neoplasm. However, it is very
operator-dependent, and as a result, its value varies
widely with locally available expertise [49, 50, 54, 57].
Computed Tomography Scan
Because of its ubiquitous availability and ability to image
the whole abdomen and pelvis, CT scan is the ideal method
for assessing whether patients demonstrate pancreatic
masses. CT scan may be particularly useful in patients
who are not jaundiced and in those in whom intestinal gas
interferes with US. CT scans with multiple detectors and
dual- or triple-phase contrast enhancement have signifi-
cantly improved the sensitivity and specificity of abdominal
CT findings. When lesions are visible, CT scanning can
also be used to direct fine-needle aspiration of pancreatic
masses. However, small tumours can still be missed even
with the most advanced CT scanning currently available.
The CT appearance of pancreatic EMP is well established
and is typically described as a multilobular homogenous
solid tumour that is hypodense as compared to the
pancreatic parenchyma. Diffuse enlargement of the
pancreatic gland has been cited in only a few cases,
and the contrast enhancement has been described as
homogeneous or heterogeneous However, these CT
features are not specific since they resemble typical
findings in other pancreatic neoplasms, including carcinoma,
islet cell tumours, lymphoma and metastases [15, 21, 24, 27,
42, 46, 59–63].
Magnetic Resonance Imaging
The role of MRI in pancreatic cancer has been less well
studied than the role of CT scanning. It does not appear to
be superior to spiral CT scanning. Some authors suggest
that this modality may be better in demonstrating pancreatic
infiltration than CT. MRI imaging features of EMP included
pancreatic enlargement and a lobulated contour. On fat-
suppressed T1-weighted MR images, the signal intensity of
the pancreas is less than that of the liver, whereas on T2-
weighted images, it is higher. Pancreatic contrast enhance-
ment is heterogeneous, but dynamic MR imaging was never
performed [38, 42, 64].
Endoscopic Retrograde Cholangiopancreatography
Endoscopic retrograde cholangiopancreatography (ERCP)
is most useful for patients in whom CT or US does not
reveal a mass lesion within the pancreas and in those in
whom the differential diagnosis includes chronic pancre-
atitis. ERCP is highly sensitive at detecting pancreatic
and/or biliary ductal abnormalities. However, the changes
observed on ERCP are not always highly specific.
Besides, it is more invasive than the other diagnostic
imaging modalities and also carries a 5–10% risk of
significant complications with the procedure. ERCP
findings provide only limited staging information, but
ERCP does have the advantage of allowing for thera-
peutic palliation of obstructive jaundice with either a
plastic or metal biliary stent. ERCP may demonstrate
smooth strictures, dilated common bile duct and proxi-
mal pancreatic duct. The demonstration of a smooth
stenosis of the biliary tree is more suggestive of an EMP
than adenocarcinoma where irregular stenosis is classical
[37, 41, 65].
Positron Emission Tomography Scanning
Positron emission tomography (PET) does not seem to offer
additional benefits to high-quality CT scan, and its role to
detect EMP has not been evaluated yet. PET scanning
combined with simultaneous CT (PET-CT) suggests that
PET-CT is more sensitive than conventional imaging for the
detection of pancreatic cancer [66]. Patients suspected of
having a pancreatic mass are initially studied with abdom-
inal TUS and/or spiral CT scanning. If a mass is detectable,
a CT- or TUS-guided biopsy of the mass follows. EUS
plays a central role in the definitive diagnosis, so if
available, high-quality EUS-guided fine-needle aspiration
(EUS-FNA) is done to confirm the disease cytologically.
All these imaging techniques are helpful in demonstrating
the pancreatic mass, but are not able to determine its exact
nature. Only immunohistochemical or flow cytometry
analysis of the lesion obtained by laparotomy or by
image-guided percutaneous biopsy or EUS-FNA can give
the final result. Nowadays, it is suggested that after
imaging/echographic finding, a percutaneous biopsy or a
EUS-FNA should be performed, eliminating exploratory
laparotomy, a high-risk procedure in this type of patient.
EUS-FNA has been proven to be the most effective
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means for making a definitive cytologic diagnosis of a
pancreatic mass since a cytologic diagnosis can be made
in 85–95% of patients.
Histopathological Findings/Immunohistochemistry
Because of its scarcity and the cytomorphologic similarity
between plasma cells and endocrine cells, EMP of the
pancreas may be confused with neuroendocrine (islet cell)
tumours of the pancreas. Immunohistochemical staining for
light chain and/or neuroendocrine markers will prevent
diagnostic error when interpreting plasmacytoid neoplasms
of any site susceptible to endocrine tumours, including the
pancreas.
In EMP, the plasma cells have round to oval eccentric
nuclei, nuclear membrane irregularity, occasional prominent
nucleoli and a fine to coarsely clumped chromatin pattern.
The cytoplasm is abundant and basophilic, with a perinu-
clear clear zone. Immunohistochemical study of a biopsy
specimen of an EMP is fundamental as it shows atypical
plasma cells. The cells express strong CD38, CD138 and
light-chain restriction.
CD20, a B cell marker, is not expressed by the malignant
cells, and this excludes the possibility of a diagnosis of a
marginal zone B cell lymphoma of mucosa-associated
lymphoid tissue lymphoma. CD56 is aberrantly expressed
in 67–79% cases, which aids in differentiating EMP from
lymphomas.
Cytogenetics and Fluorescent In Situ Hybridization
Genetic abnormalities are detected in about 33% of PCM,
and fluorescent in situ hybridization (FISH) increases the
proportion with chromosomal abnormalities to more than
90%. Cytogenetics have prognostic importance, and the
unfavourable cytogenetic risk group has a shorter median
survival than those without. The unfavourable cytogenetic
risk includes deletion of chromosome 13 or aneuploidy by
classical cytogenetics, chromosome translocations like t
(4;14) or t(14;16) or t(14;20), and the deletion of 17p13 by
FISH and has a shorter median survival than those with a
more favourable risk with the absence of unfavourable
genetics or have hyperdiploidy, t(11;14) or t(6;14) by
FISH [2].
Bone Marrow Aspiration
A bone marrow (BM) sample is essential to clarify whether
the EMP occurs in the context of a PCM. Concurrent
presence of clonal plasma cells in BM and EMP makes the
diagnosis of PCM, and the EMP is regarded as
secondary. This obviously has therapeutic relevance since
the management is more complex, requiring a combination of
diverse modalities of treatment.
Differential Diagnosis
The differential diagnosis of a pancreatic EMP includes
adenocarcinoma, focal pancreatitis, lymphoma, pancreatic
neuroendocrine tumours and metastasic disease.
– Adenocarcinoma of the ductal epithelium, a hypovas-
cular lesion that often (66%) occurs in the pancreatic
head, has a slight male predominance (60%) and is
more common in Blacks than Caucasians. These
represent approximately 85% of pancreatic masses.
The cells present a fragile, basophilic, granular cytoplasm
and nuclei with often prominent nucleoli; the slide
background shows distinctive finely vacuolated or foamy
material derived from tumour cell cytoplasm which
contrasts with the plasma cells’ high nuclear/cytoplasmic
ratio, blue cytoplasm, eccentric nucleus, perinuclear pale
zone resembling a halo and a prominent nucleoli.
– Islet cell/endocrine tumour is hypervascular andmay have
malignant potential. These represent approximately 10%
of pancreatic masses. Islet cell/endocrine tumour demon-
strates relatively small uniform neoplastic cells with a
well-preserved rim of granular-appearing cytoplasm; the
nuclei are most often eccentrically placed within the cell
cytoplasm, giving a plasmacytoid appearance, with finely
granular and evenly distributed chromatin. Immunohisto-
chemical staining for light chain and/or neuroendocrine
markers is crucial. Distinctive cytomorphology, immuno-
peroxidase characteristics and negative flow cytometry
analysis help differentiate between neuroendocrine
tumours and plasmacytoma.
– Primary or secondary lymphoma is rare but not uncom-
monly seen at autopsy in cases of non-Hodgkin’s
lymphoma (one third of cases). At autopsy, it is difficult
to distinguish whether a mass is primary or the result of
tumour infiltration from peripancreatic nodes. Pancreatic
lymphoma is often described as a large, homogeneous
mass with extrapancreatic extension, with or without
associated lymphadenopathy. Primary pancreatic lym-
phoma constitutes 0.5% of all pancreatic mass [67, 68].
– Focal/florid chronic pancreatitis could be differentiated
from plasmacytomas due to the presence of calcifica-
tions and areas of necrosis [69].
– Metastasis is rare but can occur with melanoma as well
as breast and bronchogenic carcinoma. Metastases to
the pancreas are generally multiple and associated with
known primaries, whilst plasmacytomas of the pancreas
are in almost all cases single nodular lesions.
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Treatment
There appears to be no standardized treatment for
extramedullary plasmacytomas of the pancreas. Surgery,
radiotherapy and chemotherapy with haematopoietic stem
cell transplantation have all been employed. For primary
EMP, radiotherapy and/or surgery are sufficient. Systemic
chemotherapy is required for secondary EMP.
Radiotherapy
Based on the documented radiation sensitivity of EMP, the
treatment of choice is local radiotherapy (dose of at least
4.5 Gy, depending on tumour size; the optimal dose for
local control is 40–50 Gy, delivered over 4–6 weeks) [41].
The local control rate of radiotherapy (RT) can reach 90–
97%, and the 5-year overall survival rate can be 57–61%
[70, 71].
Surgery
Solitary plasmacytoma of the tail of the pancreas can also
be managed by distal pancreatectomy in good surgical
candidates. Patients with upper aerodigestive tract EMP
who had combined surgery and radiation therapy had a
higher median overall survival (25 years) than surgical
intervention alone (median 13 years) or only radiation
therapy (median 12 years). However, in cases on non-upper
aerodigestive tract EMP, it appears that no statistical
difference in survival is observed [6]. In the literature,
cases with multifocal or bulky pancreatic involvement have
been managed with combined RT plus surgery or, in
selected cases of isolated pancreatic tail mass, surgery
alone (distal pancreatectomy) [20, 24, 33, 34, 42, 45, 56].
Surgical procedures, other than distal pancreatectomy for
isolated pancreatic tail involvement, are not commonly
performed owing to the often systemic nature of the disease
and the radical nature of these surgical procedures.
Unsuspected cases may undergo pancreatic resection
typical for pancreatic lesions with subsequent identification
of plasma cells [45].
Chemotherapy and auto-HSCT
Chemotherapeutic agents are commonly used, combined or
not with radiotherapy particularly when plasmacytomas are
secondary in nature. In eligible patients, the standard of
care of PCM is steroid–chemotherapy combinations
followed by autologous haematopoietic stem cell trans-
plantation (auto-HSCT). However, the optimal induction
therapy prior to auto-HSCT is currently not known.
Vincristine, doxorubicin (Adriamycin) and dexametha-
sone (VAD) had long been used as the standard induction
chemotherapy, but has been replaced by the advent of
novel drugs. Thalidomide (an immunomodulatory drug
with major anti-angiogenic activity) plus dexamethasone
resulted in a significantly higher response rate of 76%
versus 52% in VAD arm [72–75]. Bortezomib is a
proteasome inhibitor, PS-341. It induces apoptosis,
reverses drug resistance of multiple myeloma cells and
affects their microenvironment by blocking cytokine
circuits, cell adhesion, and angiogenesis in vivo. Bortezomib
presents a response rate of 27–38% and a 1-year overall
survival rate of 80% in patients with refractory relapsed
multiple myeloma and is also effective in multiple myeloma
with extramedullary infiltration [76–78]. Four prospective
randomized European studies have established that auto-
HSCT confers superior overall survival and/or event-free
survival when compared with standard chemotherapy
therapy [79–82]. It also results in a higher CR rate.
Multiple studies have indicated that the best preparative
regimen for autologous transplantation is melphalan
200 mg/m2. Comparison between a single with tandem
transplants has clearly shown a superior outcome with
tandem transplants. Patients who are not candidates for
transplantation should be treated with combinations of
cytotoxic drugs with the newer drugs, such as melphalan,
thalidomide or lenalidomide or bortezomib, and dexa-
methasone [83–86]. Extramedullary relapses of MM after
auto-HSCT are very resistant to conventional chemotherapy.
The role of new drugs and the optimal treatment strategy in
these cases remain to be defined.
Prognosis and Outcome
Approximately 70% of patients with EMP remain free of
disease at 10 years, whilst up to 30% develop frank PCM or
multiple extramedullary tumours. Survival in these patients
is related to the underlying systemic illness. Consequently,
the course for EMP not related to PCM is more favourable
than that of PCM or solitary plasmacytoma of the bone.
Life expectancy related to EMP of the pancreas has been
quoted as 1 day to 6 years in the literature [12–58]. In EMP
secondary to PCM, the prognosis is related to the
underlying disease. Therefore, attempts to better identify
subgroups of patients with distinct outcomes have led to the
recognition of various prognostic factors. The serum level
of β2-Microglobulin is one of the most important prognos-
tic factors in myeloma since it reflects tumour load and
renal function. Other indicators of higher-risk patients
include low serum albumin, elevated lactate dehydroge-
nase, high C-reactive protein, increased plasma cell
proliferative activity, high degree of BM replacement,
plasmablastic morphology and genetics. Two PCM staging
systems are currently used. The Durie–Salmon myeloma
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staging system, which applies commonly available clinical
parameters to predict plasma cell burden (low, interme-
diate, high) with a significant difference in survival
between each of these three tumour mass stages [87],
and an international staging system for PCM which
provides a highly significant prognostic correlation using
a combination of serum β2-Microglobulin and albumin to
define three stages with a median survival of 62, 44 and
29 months, respectively [88].
Conclusions
Pancreatic involvement by PCN is extremely rare, com-
prising <0.1% of all pancreatic masses. Among those 0.1%,
primary EMP is much less common than the EMP
secondary to PCM. Therefore, in a patient with PCM or
solitary plasmacytoma, the presence of a pancreatic mass
should raise our attention for the possibility of a pancreatic
plasmacytoma. However, an unrelated pancreatic mass,
such as an adenocarcinoma, must be excluded. Percutane-
ous biopsy or EUS-FNA is a simple and effective way to
establish the correct diagnosis of an EMP, but clonality
must be proven by immunohistochemistry or immunophe-
notyping of the biopsy specimen. Standardized treatment
for EMP of the pancreas is not defined yet. Owing to its
uncommon nature, the comparative assessment of treatment
modalities is not feasible. In the absence of such evidence,
extrapolation from the treatment of PCM seems reasonable
and has been shown to improve the extent of obstructive
jaundice in these patients.
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